Postes actifs de Dziyana Kraskouskaya
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Dunad Therapeutics Ltd.
 Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - | - |
| Directeur des opérations | - | - | |
| Fondateur | - | - |
Historique de carrière de Dziyana Kraskouskaya
Statistiques
Internationale
| Royaume-Uni | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Health Technology |
- Bourse
- Insiders
- Dziyana Kraskouskaya
- Expérience
